NCT07493603 A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease
| NCT ID | NCT07493603 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Xia Liang |
| Condition | Coronary Heart Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-01-16 |
| Primary Completion | 2027-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2026-01-16 with a primary completion date of 2027-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if Yiyang Huoluo Decoction (a custom Chinese herbal medicine) works safely and effectively to treat coronary heart disease with atherosclerosis in older adults. It also aims to find out how this herbal treatment may affect blood vessel health and repair at a cellular level. The main questions it aims to answer are: * Does adding Yiyang Huoluo Decoction to standard Western medical care improve symptoms and heart-related health in older adults with coronary heart disease and atherosclerosis? * Is Yiyang Huoluo Decoction safe for older adults to take alongside their regular heart medications? * How does this herbal treatment affect the damaged blood vessels in study participants? Researchers will compare two groups of participants to see if the combined treatment works better than standard care alone. Who can take part: Older adults diagnosed with coronary heart disease and atherosclerosis who meet the study's health and eligibility rules. What participants will do: * Be split randomly into two groups of 15 people each: one group gets standard Western heart medicine only, and the other gets standard Western heart medicine plus Yiyang Huoluo Decoction (herbal granules) * Complete the 12-week decoction treatment plan as directed by the research team * Attend scheduled study visits for health checks, blood tests, heart and blood vessel scans (such as carotid ultrasound and coronary CTA), and symptom reviews * Provide two small blood samples for research testing (samples will be destroyed after study testing is finished) * Report any side effects, discomfort, or changes in health to the research team right away All personal health information collected for this study will be kept private and confidential. Participation is completely voluntary, and participants may quit the study at any time for any reason without losing access to regular medical care.
Eligibility Criteria
Inclusion Criteria: All of the following conditions must be met simultaneously for enrollment: * ① Meet the diagnostic criteria for stable angina pectoris; * ② Classified as Grade I to III according to the Canadian Cardiovascular Society (CCS) Angina Grading Scale; * ③ Meet the diagnostic criteria for chest discomfort syndrome due to yang qi deficiency and decline (a traditional Chinese medicine pattern differentiation); * ④ Aged between 50 and 75 years old; * ⑤ Received drug-eluting stent implantation due to severe vascular stenosis (single artery ≥75%， or LM ≥50%) detected by coronary angiography; * ⑥ Able to actively comply with medical instructions and voluntarily sign the written informed consent form. Exclusion Criteria: Participants will be excluded if they meet any of the following conditions: * ① Diagnosed with acute coronary syndrome (including acute ST-segment elevation myocardial infarction, acute non-ST-segment elevation myocardial infarction, and unstable angina pectoris) after relevant examinations; * ② Suffer from chest pain caused by non-cardiac diseases other than stable angina pectoris; or have complicated severe hypertension (systolic blood pressure ≥ 180mmHg and/or diastolic blood pressure ≥ 110mmHg), severe cardiopulmonary insufficiency, or malignant tumor; * ③ Have severe endocrine, hematological or rheumatic immune system diseases, severe hepatic and renal dysfunction, active gastrointestinal bleeding, or mental illness; * ④ Have an allergic constitution or a history of allergic reactions to traditional Chinese medicine; * ⑤ Have incomplete major baseline data that may affect the trial results, or have participated in other clinical trials recently.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07493603 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 75 Years, studying Coronary Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07493603 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07493603 currently recruiting?
Yes, NCT07493603 is actively recruiting participants. Contact the research team at 407928215@qq.com for enrollment information.
Where is the NCT07493603 trial being conducted?
This trial is being conducted at Huzhou, China.
Who is sponsoring the NCT07493603 clinical trial?
NCT07493603 is sponsored by Xia Liang. The trial plans to enroll 30 participants.